Behavioural activation vs CBT
quality of life (continuous)up to 6 months (8 weeks) · depression in adults
1 finding from 1 review
- no estimate extracted2 studies · 268 participantsModerate
Findings
What do systematic reviews say?
1,368 questions · 1,413 findings · 89 reviews · Common Mental Disorders
No studies found 232 · 16.4%GRADE not reported 82 · 5.8%Very low 395 · 28%Low 331 · 23.4%Moderate 341 · 24.1%High 32 · 2.3%
Behavioural activation vs no treatment
quality of life (continuous)up to 6 months (2 weeks) · depression in adults
1 finding from 1 review
- no estimate extracted1 study · 118 participantsHigh
Behavioural activation vs no treatment
Anxiety · depression in adults
1 finding from 1 review
- no estimate extracted1 study · 30 participantsLow
Behavioural activation vs treatment
treatment efficacyup to 6 months (5‐12 weeks) · depression in adults
Behavioural activation probably leads to higher treatment efficacyup to 6 months (5‐12 weeks) compared with treatment (moderate certainty).
1 finding from 1 review
- RR 1.4 [1.1, 1.79]7 studies · 1533 participantsModerate
Behavioural activation vs treatment
treatment acceptabilityup to 6 months (5‐12 weeks) · depression in adults
Behavioural activation showed no clear difference in treatment acceptabilityup to 6 months (5‐12 weeks) compared with treatment (moderate certainty).
1 finding from 1 review
- RR 1.64 [0.81, 3.31]14 studies · 2518 participantsModerate
Behavioural activation vs treatment
quality of life (continuous)up to 6 months (2 weeks) · depression in adults
1 finding from 1 review
- no estimate extracted6 studies · 1299 participantsVery low
Behavioural activation vs treatment
social adjustment and functioning (continuous)up to 6 months (12 weeks) · depression in adults
1 finding from 1 review
- no estimate extracted2 studies · 88 participantsLow
Behavioural activation vs treatment
Anxiety · depression in adults
1 finding from 1 review
- no estimate extracted4 studies · 1063 participantsModerate
Behavioural activation vs treatment
adverse events(8‐10 weeks) · depression in adults
1 finding from 1 review
- no estimate extracted3 studies · 1471 participantsModerate
Behavioural activation vs CBT
social adjustment and functioning (continuous)up to 6 months (12 weeks) · depression in adults
1 finding from 1 review
- no estimate extracted2 studies · 111 participantsVery low
Behavioural activation vs CBT
Anxiety · depression in adults
1 finding from 1 review
- no estimate extracted4 studies · 646 participantsModerate
Behavioural activation vs CBT
adverse events (16 weeks) · depression in adults
1 finding from 1 review
- no estimate extracted2 studies · 398 participantsModerate
Behavioural activation vs third‐wave CBT
treatment efficacy up to 6 months (4‐8 weeks) · depression in adults
Behavioural activation showed no clear difference in treatment efficacy up to 6 months (4‐8 weeks) compared with third‐wave CBT (low certainty).
1 finding from 1 review
- RR 1.1 [0.91, 1.33]2 studies · 98 participantsLow
Behavioural activation vs third‐wave CBT
Secondary outcome: acceptability of treatment · depression in adults
Behavioural activation showed no clear difference in treatment acceptability up to 6 months (4‐8 weeks) compared with third‐wave CBT (low certainty).
1 finding from 1 review
- RR 0.84 [0.33, 2.1]3 studies · 147 participantsLow
Behavioural activation vs any comparator
Quality of life (medium term: 12 months) · depression in adults with non‐communicable diseases
1 finding from 1 review
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 80 participantsLow
Behavioural activation vs any comparator
Social adjustment and functioning (medium term: 12 months) · depression in adults with non‐communicable diseases
2 findings from 1 review
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 80 participantsLow
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 80 participantsLow
Behavioural activation vs any comparator
Improvement in anxiety symptoms (medium term: 12 months) · depression in adults with non‐communicable diseases
2 findings from 1 review
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 80 participantsLow
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 80 participantsLow
Behavioural activation vs any comparator
Acceptability · depression in adults with non‐communicable diseases
Behavioural activation showed no clear difference in treatment acceptability (short term: 2 months) compared with any comparator (low certainty).
2 findings from 1 review
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyRR 1.81 [0.68, 4.82]1 study · 80 participantsLow
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyRR 0.88 [0.25, 3.1]1 study · 101 participantsLow
Behavioural activation vs any comparator
Quality of life (short term: 6 months) · depression in adults with non‐communicable diseases
1 finding from 1 review
- Behavioural activation therapy for depression in adults with non‐communicable diseases 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 80 participantsLow
Bupropion XL vs placebo
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to lower incidence of SAD (SIGH‐SAD score ≥ 20) compared with placebo (moderate certainty).
1 finding from 1 review
- Second‐generation antidepressants for preventing seasonal affective disorder in adults 2019 · Cochrane Headline outcomes onlyRR 0.56 [0.44, 0.72]3 studies · 1100 participantsModerate